Credit Suisse Raises Price Target on Endo Pharmaceuticals Holdings (ENDP), Maintains Neutral Rating
Tweet Send to a Friend
Credit Suisse is reiterating their Neutral rating on shares of Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) following their strong 4Q10 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
